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Abstract: Cyclic peptides are a class of compounds with high 
therapeutic potential, possessing bioactivities including anti-tumour 
and anti-viral (including anti-HIV). Despite their desirability, efficient 
design and production of these compounds has not yet been 
achieved. The catalytic mechanism of patellamide macrocyclization 
by PatG macrocyclase domain has been investigated using 
computational methods. We applied a quantum 
mechanics/molecular mechanics (QM/MM) methodology, specifically 
ONIOM(M06/6-311++G(2d,2p):ff94//B3LYP/6-31G(d):ff94). The 
mechanism proposed here begins with a proton transfer from 
Ser783 to His 618 and from the latter to Asp548. Nucleophilic attack 
of Ser783 to the substrate leads on to the formation of an acyl-
enzyme covalent complex. The leaving group (AYDG) of the 
substrate is protonated by the substrate’s N-terminus leading to the 
breakage of the P1-P1’ bond. Finally, the substrate’s N-terminus 
attacks the P1 residue, decomposing the acyl-enzyme complex 
forming the macrocycle. We found that the formation and 
decomposition of the acyl-enzyme complex have the highest 
activation free energies (21.1 kcal.mol-1 and 19.8 kcal.mol-1 
respectively), typical of serine proteases. Understanding the 
mechanism behind the macrocyclization of patellamides will be 
important to the application of the enzymes in the pharmaceutical 
and biotechnological industries. 
Introduction 
The pharmaceutical industry has become excellent at 
developing small-molecule drugs (below 600 MW) hitting 
classical compact binding sites. However, there remain a large 
number of non-classical targets with extended binding sites 
which cannot be modulated using small molecules, but instead 
need biologics (antibodies/native peptides) to obtain a 
therapeutic effect. Of the top selling drugs on the market 7 out of 
10 are biologics aimed at complex diseases such as rheumatoid 
arthritis and cancer.[1] Macrocycles (500-2000 Da) are a third 
class of therapeutics which are able to modulate the same 
complex, extended, targets as biologics, but are easier to 
administer, hit intracellular targets and may have a lower 
associated cost of goods.[2] Of the 68 approved macrocycle 
pharmaceuticals, 27 are cyclic peptides[3], 1 of which is orally 
available. Cyclic peptides have a number of advantages over 
linear ones including reduced susceptibility to metabolism, 
improved membrane permeability and an entropic advantage on 
binding to a target. The pharmaceutical industry is struggling 
with two aspects of macrocycles: their design and efficient 
production. Most processes to generate peptide macrocycles 
rely on the use of high dilution conditions to prevent 
oligomerisation, using controlled addition conditions making 
these approaches non-viable for large-scale synthesis.[4a,b] 
Alternative synthetic approaches have been developed including 
on-bead macrocyclization requiring attachment to the solid 
support via an amino acid side chain and a 3-dimensional 
orthogonal protecting group strategy.[5] Biological methods of 
macrocyclization include sortase-mediated ligation, but this 
results in the incorporation of the pentapeptide LPXTG in the 
cyclic peptide where X is variable.[6]  
Efficient formation of cyclic peptides without leaving a residual 
sequence in the final macrocycle is desirable. Natural cyclic 
peptides can be formed either via a non-ribosomal peptide 
synthetase route, or the more recently discovered superfamily of 
ribosomally produced and post-translationally modified peptides 
(RiPPs).[5] RiPPs are formed using a common biosynthesis, in 
which a precursor peptide, comprised of a leader sequence 
followed by a core peptide often flanked by signal sequences, is 
modified via the action of processing enzymes, which install 
post-translational modifications in the core peptide. 
The matured core peptide is then removed from the leader and 
signal sequences, liberating the mature, active peptide. In many 
cases, this last step results in the formation of a peptide 
macrocycle. Three RiPP macrocyclases have been defined; 
butelase-1 an asparagine/aspartate peptide ligase that is 
responsible for the formation the plant cyclic peptide cyclotides[7], 
GmPOPB, a prolyl oligopeptidase involved in α-amanitin 
biosynthesis[8] and PatG macrocyclase (PatGmac), involved in 
the biosynthesis of the cyanobactins which are cyanobacterially 
derived azole/azoline containing cyclic peptides.[9] The 
requirements of the PatGmac are a core peptide sequence of 6-
11 residues which may include D-amino acids or unnatural 
amino acid residues, an AYD(GE) signal at the C-terminus 
which is not incorporated in the final cyclic peptide, and a cyclic 
residue (proline or thiazoline) at the C-terminal of the core 
peptide which is included in the macrocycle.[10] 
Our structural investigations have delineated the mode of action 
of PatGmac and have led to an understanding of the 
requirements described above.[9] PatGmac is a subtilisin-like 
serine protease produced by Prochloron sp. which is an obligate 
symbiont of the seasquirt Lissoclinum patella.[11] The more 
normal extended conformation of the peptide substrate is 
prevented by bulky enzyme residues (Met660/Arg686/Phe684) 
protruding into the binding groove as a consequence of a 
disulphide bridge formation between Cys685 and Cys724. As a 
result of this only a bent substrate peptide can bind, and this is 
facilitated by the conformational properties of the proline or 
thiazoline residue at  
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Figure 1. Model used in the QM/MM calculations. The high layer is composed by 91 atoms, which includes the residues of the catalytic triad (Ser783, His618 
(side chain until Cα) and Asp548 (side chain until Cβ)), Asn717 (side chain until Cγ) and by P1(Cys), P1’(Ala), P2’(Tyr) residues and the terminal Ile of the 
substrate.
the P1 position (P3, P2, P1 are the residues before the cleavage 
site and P1’, P2’ those after the cleavage site). 
The unique structural feature of PatGmac is an insertion loop in 
the normal subtilisin sequence generating a helix-turn-helix motif 
forming a protective lid over the active site. The AYD signal at 
the C-terminus of the core peptide binds via the aspartate 
residue to basic residues in the helix-turn-helix motif 
(Arg589/Lys594/Lys598). After binding the substrate peptide, a 
normal serine protease mechanism ensues, but access by water 
is prevented by the strongly bound AYD signal, thus allowing the 
amino terminus of the core peptide to loop around and attack the 
acyl complex, resulting in cleavage of the recognition signal and 
cyclization of the core peptide. 
 
Figure 2. Representation of the catalytic mechanism proposed for PatGmac.[9] 
 
In this work, we explored the mechanism of the reaction 
catalysed by PatGmac using computational methods, in order to 
describe, with atomistic detail, the most plausible catalytic 
mechanism of this enzyme. Considering the ability of the 
enzyme to macrocyclize an extensive range of nonactivated 
substrates, the data obtained in the present study has wide 
implications in a number of areas. Fully understanding the 
mechanism of PatGmac may lead to engineered analogues with 
improved properties which accept an even broader substrate 
range this increasing its utility in a range of pharmaceutical and 
biotechnology applications. 
 
Figure 3. Structure of the reactants highlighting the most relevant distances 
for the first mechanistic step. 
Results and Discussion 
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In previous work, some of us proposed a catalytic mechanism 
for PatGmac[9] (Figure 2) based on the structure of the enzyme 
macrocyclase domain and biochemical characteristics. It was 
suggested that the first step of the reaction is the nucleophilic  
Figure 4. Representation of the structures of the first transition state (TS1) and the intermediate (INT1) on the first step 
Figure 5. Representation of the structures of the transition state (TS2) and the intermediate (INT2) of the second step of the macrocyclization reaction. 
attack of Ser783, aided by His618 which acts as a base, to the 
P1’ carbonyl group of the substrate leading to the formation of 
an enzyme-substrate tetrahedral intermediate. After this first 
attack, the AYDG peptide is cleaved by protonation of the 
leaving group’s N-terminal by His618. Lastly, the N-terminus of 
the substrate attacks the carbonyl group of the cysteine (P1) 
forming the macrocycle (Figure 2). In order to test the proposed 
mechanism and get a complete and detailed description of this 
catalytic mechanism, we have performed QM/MM calculations. 
The first reaction step 
In the reactants optimized structure, Ser783 is at 3.89 Å from the 
carbon atom of P1 and correctly oriented to begin the attack. 
Asp548 is hydrogen bonded to His618 (1.69 Å) and the latter is 
hydrogen bonded to Ser783 (1.54 Å) (Figure 3). The catalytic 
reaction begins with the typical proton transfer on the serine 
protease’s catalytic triad, from Ser783 to His618. We defined the 
distance between Nδ1 of His618 and the Hγ of Ser783 as the 
putative reaction coordinate. As the proton of Ser783 was being 
transferred to His618, the proton of the His618 imidazole ring 
spontaneously moved to Asp548 O- atom. We noticed that the 
structures of the reactants (Asp-COO-/H-His/OH-Ser) (Figure 3) 
and of the generated intermediate (Asp-COOH/His-H/-O-Ser) 
(Figure 4) are very close in energy (2.4 kcal.mol-1). The free 
energy barrier was calculated in 2.5 kcal.mol-1. At the transition 
state structure, both the proton transferred from Ser783 to 
His618 and the one that was consequently transferred from 
His618 to Asp548, assume an intermediate position between the 
respective residues (Figure 4).  
The vibrational frequency analysis revealed an imaginary 
frequency corresponding to the reaction coordinate (an 
antisymmetric stretch involving both proton transfers) confirming 
the nature of the transition state (996.52 i.cm-1). However, 
another small negative frequency (31.30 i.cm-1) was found, as a 
consequence of the more relaxed geometry optimization.  
Thermal corrections and zero point energies were included in 
the free energy calculation, despite the existence of a very small 
second imaginary constant. These corrections have a small 
contribution to the corresponding free energy values in 
agreement to what has been reported in the literature regarding 
proton transfers between catalytic residues (ca. 1.2 kcal/mol).[30] 
As the barrier was extremely shallow and not rate-limiting it was 
not optimized further. 
The small free energy of reaction suggests that both structures 
may exist simultaneously being the latter the most favourable to 
initiate the catalytic reaction. The possibility of the first step to 
begin with a direct nucleophilic attack of Ser783 to the substrate, 
with the proton transfer occurring during the attack was also 
considered. Defining the distance between Ser783 and P1 as 
reaction coordinate, it was found that the energy barrier 
associated with this alternative is very high (>30 kcal.mol-1). Our 
proposal for the first step has a much smaller energy barrier  
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Figure 6. Representation of the structures of the transition state (TS3) and the intermediate (INT3) of the third step of the reaction.
Figure 7. Representation of the structures of the transition state (TS4) and the intermediate (INT4) of the fourth step of the reaction. 
(2.5 kcal.mol-1) indicating that the proton transfer leading to an 
intermediate with enhanced nucleophilicity for attack at the 
substrate amide. 
The second reaction step 
The deprotonated Ser783 attacks the P1 carbonyl group forming 
the enzyme linked tetrahedral intermediate. A study of this step 
was made with a linear transit scan using the optimized structure 
after the proton transfer described above as reactants, and 
defining the distance between the Oγ of Ser783 and the carbonyl 
carbon of P1, which is initially 3.90 Å (Figure 4), as the reaction 
coordinate to be scanned. 
A conformational change in His618 took place before the 
formation of the tetrahedral intermediate, with the approximation 
of Ser783 to the P1 carbonyl group, His618 changed its rotamer 
by rotating around the Cβ-Cγ bond, breaking the hydrogen bond 
with Ser783 hydroxyl and forming another with the Ser783 
carbonyl, while keeping the hydrogen bond with Asp548. 
Additionally, a hydrogen bond between the attacking oxygen of 
Ser783 and Asn717 amine was formed (Figure 5). This 
conformational change led to a stable intermediate (INT2) before 
Ser783 has completed the nucleophilic attack on the substrate. 
A free energy barrier of 4.8 kcal.mol-1 in relation to INT1 was 
found, characterized by one imaginary frequency (31.83 i.cm-1) 
clearly corresponding to the reaction coordinate. We will refer to 
this point as TS2 (Figure 5). In that structure His618 is placed 
between Ser783 side chain and carbonyl oxygen atoms at 2.22 
Å and 2.28 Å respectively. Ser783 which initially was at 3.90 Å 
from the P1 residue stays at 3.57 Å on TS2 and at 3.61 Å on 
INT2. 
The third reaction step 
Starting from the INT2 optimized structure, the attack of Ser783 
to the substrate was conducted until the formation of the 
tetrahedral intermediate, using the distance between the Ser783 
deprotonated oxygen and the P1 carbonyl carbon (3.62 Å) as 
reaction coordinate (Figure 5). This attack had a free energy 
barrier of 21.1 kcal.mol-1 in relation to INT2. This rate-limiting 
transition state (TS3) was further freely optimized, having one 
imaginary frequency (744.16 i.cm-1) that corresponds to the 
coordinated stretching of the Ser783 oxygen-P1 carbonyl carbon 
and of the N-H bond of the terminal amino group of the substrate. 
This proton, together with the Asn717 amine, constitutes the 
oxyanion hole which stabilizes the oxyanion of the acyl-enzyme 
complex. The interactions between them may consist of low-
barrier hydrogen bonds (LBHB) considering, particularly, their 
short length (< 2.0 Å). The existence of LBHB between the 
oxyanion and the oxyanion hole in serine proteases has already 
been proposed[31] although others have considered them to be 
simple electrostatic interactions.[32] In this case we can clearly 
see the transition from an electrostatic hydrogen bond in the 
reactants to a hydrogen bond where the proton is shared 
between both acceptors, commonly known as a single-well 
hydrogen bond, which corresponds to an extreme case of a low 
barrier hydrogen bond where the barrier vanishes. However, we 
note that this structure, achieved at the transition state, is not a 
stable, long-lived interaction. Whether or not this kind of 
interactions are catalytic or anticatalytic is a matter of debate.[33] 
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Figure 8. Representation of the structures of the fifth transition state (TS5) and products of the fifth step.
 
 
 
 
 
 
 
 
 
Figure 9. Potential energy surface (PES) for the macrocyclization reaction catalysed by PatGmac. The energies were obtained at ONIOM(M06/6-
311++G(2d,2p):Amber//B3LYP/6-31G(d):Amber) level.
The fourth reaction step  
The conformational rearrangement that His618 makes it unlikely 
that it protonates the leaving group in the third step of the 
catalytic reaction, as initially proposed and which is typical for 
other serine proteases.[32] After the rearrangement His618 stays 
at 5.97 Å from P1’ and not adequately oriented (Figure 6), the 
substrate’s N-terminal (charged) amine group would be the most 
suitable candidate to protonate P1’ amine. 
Therefore, we conducted a linear transit scan using the distance 
between the NH3+ terminal proton and the P1’ amine group, 
which is 2.01 Å in the INT3 geometry, as reaction coordinate 
(Figure 6). A transition state (TS4) was then freely optimized and 
an imaginary frequency (1184.98 i.cm-1) was found which 
corresponds to an asymmetric stretch between the transferred 
proton and the two nitrogen atoms (Figure 7). We found an 
energy barrier of 3.1 kcal.mol-1 relatively to INT3. With the 
transfer of the proton, a very stable intermediate (INT4) is 
obtained (ΔGstep4 = - 23.8 kcal.mol-1), the bond P1-P1’ is 
cleaved but the AYDG tetrapeptide is retained on the active site 
of the enzyme, at 2.95 Å from P1, on the INT4 optimized 
structure (Figure 7). 
The fifth reaction step – Macrocyclization of the substrate 
To complete the catalytic mechanism of PatGmac, the 
substrate’s N-terminus attacks the carbon atom of P1 carbonyl 
group closing the macrocycle. We have used the distance 
between the N-terminus and the P1 carbonyl carbon (4.99 Å) as 
reaction coordinate. We found that during this step the N-
terminus donates a proton to Ser783, consequently 
decomposing the enzyme-substrate tetrahedral structure since 
the bond between P1 and Ser783 is cleaved. The macrocycle is 
formed and the AYDG peptide which was at 2.95 Å from P1 at 
the beginning of this step is further displaced. This step had a 
free energy barrier of 19.8 kcal.mol-1, in relation to INT4, and 
originates very stable products (ΔGstep5 = - 42.6 kcal.mol-1) 
(Figure 8), being the displacement of the AYDG peptide an 
important factor contributing to the great stability of the products. 
The freely optimized TS5 geometry shows one imaginary 
frequency (136.59 i.cm-1), corresponding to the reaction 
coordinate. The present description of this step differs from the 
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first proposed mechanism[9], in that, the substrate’s N-terminus 
donates a proton to Ser783 rather than His618.  
 
Scheme 1. General scheme for the catalytic mechanism of PatGmac 
predicted by earlier experiments and by present QM/MM calculations. 
Energetic profile of the PatGmac catalytic mechanism  
Figure 9 shows the energetic pathway of the macrocyclization 
reaction catalyzed by PatGmac at the ONIOM(M06/6-
311++G(2d,2p):Amber//B3LYP/6-31G(d):Amber) level.  
According to these results, the TS2 has the highest free energy. 
However, that is not the rate-limiting step since both TS3 and 
TS5 have higher energy barriers relatively to the preceding 
intermediate which are very stable. These TS represent the 
formation of the enzyme-substrate complex (TS3) and the 
formation of the macrocycle and accompanying decomposition 
of the acyl-enzyme complex (TS5). The TS3 has an energy 
barrier slightly higher than TS5 (21.1 kcal.mol-1 and 19.8 
kcal.mol-1 respectively), but given their proximity, both will be 
relevant for the observed rate of this reaction (note that the 
difference between the two is very narrow and probably close to 
the accuracy of the methodology for relative energies between 
similar molecular structures). Both the formation and 
decomposition of the tetrahedral complex have been identified 
as slow steps previously[32,34] consistent with our results here 
and with our previous mass spectrometric observation of the 
acyl PatGmac intermediate. The PES of the reaction shows that 
it is strongly exothermic with the products 76.0 kcal.mol-1 more 
stable than the reactants. All mechanistic steps are exothermic 
with step 3 (formation of the acyl-enzyme intermediate) being 
the sole exception.  
The reaction rates reported for PatGmac are approximately 1 
per day.[10,35] Thus, the Gibbs free energy barrier for the 
macrocyclization reaction may be estimated from the transition 
state theory, resulting in an observed experimental free energy 
of ≈ 24 kcal.mol-1, which is a comparable value to the obtained in 
the present work (21.1 kcal.mol-1).  
Conclusions 
We have explored by computational approaches the 
macrocyclization reaction catalyzed by PatGmac. Our results 
showed that the mechanism followed by this enzyme is different 
to those typical of serine proteases albeit with some similarities 
(Scheme 1). The typical proton transfer on the Ser-His-Asp 
catalytic triad occurs, as we describe in the first reaction step, as 
well as the formation of the acyl-enzyme intermediate (second 
mechanistic step). We found, however, that the protonation of 
the AYDG leaving group of the substrate is most probably made 
by the substrate’s NH3+ terminus and not by His618 (Scheme 1), 
due to steric impediments (Figure 2). This enzyme differs from 
typical serine proteases where deacylation of the enzyme-
substrate complex occurs by an attack of a water molecule[32] 
regenerating the enzyme. In PatGmac, the active site is shielded 
from water[9] and because of that, the deacylation is achieved by 
the attack of the substrate’s N-terminus which also protonates 
the acyl complex. The formation of the peptide bond is common 
to macrocyclization of other peptide substrates, namely other 
cyanobactins.[9,36]  
This new mechanism differs from that proposed previously 
(Figure 2, Scheme 1)[9] the central difference is His618 
undergoes a conformational rearrangement and does not 
protonate the leaving group. Rather it is the incoming substrate 
amino terminus that protonates the leaving group. 
This study contributes to further understanding the mechanism 
of macrocyclization of PatG substrate. As cyclic peptides have 
been seen as having great interest for industry, particularly 
pharmaceutical, more knowledge about their natural synthesis 
also contributes to improve the efficiency of large scale 
production of such compounds. The findings in this work 
suggest that adapting the enzyme process to utilize different 
substrates would need careful consideration of the pKa of the 
incoming nucleophile. Regarding the active site residues, the 
Asp His Ser triad is mandatory for the function of the enzyme 
and have to be maintained in any engineered analogue while 
Asn717 stabilizes the tetrahedral-intermediate.  
Viable options to increase the reaction rate have to focus on the 
rate-limiting step. For so, the most promising way to achieve 
catalysis would be to optimize the oxyanion hole.  
Possibly the presence of a positively charged residue at position 
717 (i.e. Lys) would further favour the nucleophilic attack of 
Ser783 to the substrate which we found that it is a rate limiting 
step of the reaction. However, the size of Lys and the proximity 
with the positive N-terminus are obstacles for the correct 
placement and protonation of the lysine. 
Methods 
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We started the modelling of the system using an X-ray structure of the 
subtilisin-like domain of the PatGmac enzyme containing an analogue of 
the substrate in the active site (PDB: 4AKT, 2.63 Å resolution). This 
structure had a mutation (His618Ala) on the catalytic triad of the active 
site (Asp548, His618 and Ser783) which was reverted by superimposition 
with a structure of the free enzyme (PDB: 4AKS, 2.19 Å resolution) that 
contained the original residue. The coordinates of Ala618 on the 4AKT 
structure were then replaced by those of His618 of the free enzyme 
structure. The hydrogen bonding network between the three residues of 
the catalytic triad and the proximity between the deprotonated nitrogen of 
the imidazole ring of His618 and the hydroxyl group of Ser783, observed 
on the free enzyme structure, is mandatory to generate a productive 
conformation and to initiate the catalytic mechanism. Thus, we naturally 
assumed that the rotameric state and position of His618 is similar in the 
free enzyme and in the enzyme complexed with the substrate. 
Additionally, in the X-ray structure, a loop composed by residues 651-657 
was missing and was modelled using the program MODELLER.[12] This 
loop is located away from the active site (> 10 Å), thus, the modelling 
performed should not have a significant effect on the study of the 
catalytic mechanism. One natural substrate has the sequence Ile-
MeOxH-Ala-ThH-Ile-OxH-Phe-ThH-Ala-Tyr-Asp-Gly, the (Ala-Tyr-Asp-
Gly) are the recognition residues cleaved (at the ThH-Ala bond) during 
the reaction (ThH = thiazoline, OxH = oxazoline, MeOxH = methyl 
oxazoline). The mimic peptide on the 4AKT structure had a different 
sequence (Val-Pro-Ala-Pro-Ile-Pro-Phe-Pro-Ala-Tyr-Asp-Gly) in which 
the azoline heterocycles had been replaced by Pro. Hence, the 
heterocycles that on the X-Ray structure were mimicked by prolines, 
were corrected and missing parts were modelled in GaussView.[13] We 
have preserved the original coordinates for most of the residues of the 
substrate. Figure SI-1 shows the original precursor peptide and the 
modelled peptide. We used the X-leap[14] software to protonate the 
complex, assuming that all residues were in their physiological 
protonation states, and 23 Na+ counter-ions were added to neutralize the 
charge of the system. Additionally, we surrounded the system with 15830 
water molecules using a truncated rectangular box of TIP3P water 
molecules with a minimum distance of 12 Å between any atom of the 
protein and the faces of the box. 
We performed a two-step minimization using the Amber 12[14] simulation 
package (parm 99SB force field) in order to relax the system by removing 
eventual tensions and clashes. First, the water molecules and counter-
ion were minimized with the remainder of the system fixed (steepest 
descent algorithm for the first 500 cycles, and conjugate gradient 
algorithm for the last 1500 steps); and, second, the position of all atoms 
(steepest descent algorithm for the first 5000 cycles, and conjugate 
gradient algorithm for the last 10000 steps) of the model was minimized. 
We ran molecular dynamics (MD) simulations, starting from the structure 
obtained after the minimization procedure, to see if the modelled 
structure was stable and preserved. First we warmed the system from 0 
to 300 K in a 200 ps long simulation maintaining a constant volume and 
using periodic boundary conditions. 
Then, a 15 ns production run was conducted using periodic boundary 
conditions with the isobaric-isothermal ensemble defining a pressure of 1 
atm and a temperature of 300 K using the Langevin thermostat and the 
Berendsen barostat for that purpose. The cutoff for the Lennard-Jones 
interactions was set to 10 Å. The Coulomb interactions were treated 
using the Particle Mesh-Ewald (PME) method, with a cutoff of 10 Å for 
the real part of the sum. The time step of the simulation was 2 fs. The 
potential energy of the system was treated with the LeapFrog integration 
algorithm. 
A structure of PatGmac complexed with substrate was taken from the 
MD simulation and was used as the starting point for the study of its 
reaction mechanism. We have chosen a structure of the system (after the 
equilibration) whose conformation was productive for the beginning of the 
catalytic cycle, which means that the distance between Ser783 and the 
substrate, and between the substrate’s N-terminus and P1 had to be 
small and appropriate for chemical reaction. The analysis of the 
trajectories has shown that, after the equilibration, these criteria are met 
in most of the structures, hence, the entropic cost for reaching a 
productive conformation should not be significant. To investigate the 
potential energy surface (PES) along the mechanism of the 
macrocyclization reaction we performed QM/MM calculations, widely 
used in enzymatic studies[15-18] applying an ONIOM[19] scheme as 
implemented in the Gaussian 09 software package.[20] The system, 
containing a total of 5200 atoms, was divided into a “QM layer”, 
containing 91 atoms (Figure 1), and an “MM layer” which were treated at 
DFT and classical MM levels respectively. The high layer includes the 
catalytic triad (Ser783, His618 (side chain until Cα) and Asp548 (side 
chain until Cβ)), Asn717 (side chain until Cγ) and P1 (Cys), P1’ (Ala), P2’ 
(Tyr) residues and the terminal Ile of the substrate. A list of the atoms in 
the QM layer is given in table SI-1. For the QM layer we employed the 
B3LYP functional using 6-31G(d) basis set for geometry optimizations, 
which was shown to provide accurate results in previous studies[21-24], 
while in the low layer we used the AMBER parm 99SB force field. We 
used hydrogen atoms as link atoms where covalent bonds were in 
between the two layers. The interaction between the two layers was 
treated using an electrostatic embedding scheme. The study of each 
mechanistic step began by conducting linear scans along the reaction 
coordinates. These corresponded to specific interatomic distances that 
connected the reactants to the products of each hypothesized reaction 
step. The precise reaction coordinates that were assumed are described 
in the main text, when each reaction step is discussed.  The structures of 
the reactants, intermediates, transition states (TS) and products were 
then fully optimized, starting with the guesses taken from the linear 
transit scans, for the rate-limiting steps. In the case of chemical steps 
with very shallow barriers we have used the highest energy structure of 
the linear transit scan as very good approximations of the transition state. 
This procedure was motivated by the great complexity of performing free 
transition state geometry optimization in this very large and 
heterogeneous system. The differences in free energy that we got when 
we compared the two procedures (i.e. taking the structure from the 
adiabatic mapping and making a free geometry optimization, both 
alternatives calculated for the rate-limiting steps) were 0.4 and 2.6 
kcal.mol-1. We performed vibrational frequency calculations for every 
stationary point, with those of the reactant, intermediates and product 
having no imaginary frequencies and those of the TS having just one, 
which in all cases was clearly related to the reaction coordinate. Even 
though the identity of the minima connected to each transition state was 
clear from the liner transit scans, and was further supported by the 
observation of the relevant normal mode, we ran further IRC calculations 
(albeit not to the full extent of the explored PESs), starting from the 
obtained TSs, to confirm that the minima that were connected to the TS 
were the ones that we were expecting. The final energies were obtained 
conducting single-point (SP) energy calculations on the optimized 
geometries using different density functionals (M06, B1B95 and 
mPWB1K in addition to B3LYP), known to have a good performance for 
thermodynamics and kinetics, and a larger basis set, 6-311++G(2d,2p), 
in the QM layer to improve the accuracy of the results. Table SI-2 shows 
the activation and reaction energies obtained with the different 
functionals. They provide a PES that translates into the same mechanism 
and are qualitatively equivalent. The values obtained with B3LYP seem a 
bit elevated comparatively to those obtained with the other functionals. 
The energy barriers for each step are similar in all cases. However, with 
B3LYP and M06 the energy barrier to TS3 is slightly higher than the 
barrier to TS5 whereas with mPWB1K and B1B95 the opposite is 
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observed. In the discussion we considered the results of the M06 
functional because it has been shown to be the most appropriate for the 
description of the thermodynamics and kinetics of the chemistry of main-
group elements.[25-27] We have calculated also the zero-point energy, the 
entropy and the thermal corrections to obtain Gibbs free energies at 
298.15 K, which is a comparable temperature to that of the water where 
the Indo-Pacific seasquirt Lissoclinum patella naturally occurs.[28] To 
calculate the entropy and free energy we have employed the particle in a 
box/rigid rotor/harmonic oscillator formalism. This is a physically clear 
and rigorous formalism to calculate the entropy and free energy of a 
system within a single-conformation model.  
GD3 dispersion[29] was included in the single point calculations as 
implemented in Gaussian 09 D.01. 
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